Iovance Biotherapeutics, Inc. (IOVA)
Company Info
Highlights
$1.17B
-$1.28
$163.35M
$41.24M
-$255.01M
$2.70 - $13.20
$20.08
23.88%
7.49
Share Price Chart
Loading data...
Compare to other instruments
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Iovance Biotherapeutics, Inc., comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Iovance Biotherapeutics, Inc. (IOVA) returned -57.16% year-to-date (YTD) and -76.33% over the past 12 months. Over the past 10 years, IOVA returned -11.50% annually, underperforming the S&P 500 benchmark at 10.43%.
IOVA
-57.16%
11.23%
-74.19%
-76.33%
-38.62%
-11.50%
^GSPC (Benchmark)
-3.70%
13.67%
-5.18%
9.18%
14.14%
10.43%
Monthly Returns
The table below presents the monthly returns of IOVA, with color gradation from worst to best to easily spot seasonal factors. Returns are adjusted for dividends.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025 | -20.95% | -27.52% | -21.46% | 7.81% | -11.70% | -57.16% | |||||||
| 2024 | -4.92% | 105.82% | -6.85% | -20.51% | -24.62% | -9.68% | 8.85% | 33.56% | -19.47% | 11.18% | -10.73% | -20.60% | -8.98% |
| 2023 | 24.57% | -8.42% | -16.19% | -7.69% | 54.96% | -19.45% | 3.13% | -16.80% | -24.67% | -16.04% | 58.90% | 33.94% | 27.23% |
| 2022 | -12.78% | -5.89% | 6.25% | -9.01% | -55.45% | 63.56% | 5.53% | -7.98% | -10.63% | -2.51% | -31.48% | -0.16% | -66.53% |
| 2021 | -5.52% | -14.92% | -15.12% | -0.69% | -40.94% | 40.12% | -14.41% | 8.08% | 2.45% | -1.42% | -22.99% | 1.98% | -58.86% |
| 2020 | -21.46% | 51.38% | -9.02% | 7.38% | -0.19% | -14.46% | 5.90% | 14.65% | -1.23% | 8.38% | 8.77% | 19.56% | 67.63% |
| 2019 | 3.39% | 12.24% | -7.40% | 19.87% | 43.42% | 49.97% | 0.29% | -14.56% | -13.37% | 16.10% | 8.05% | 21.24% | 212.77% |
| 2018 | 94.37% | 11.58% | -2.59% | -14.20% | 0.69% | -12.33% | 10.94% | 24.65% | -36.44% | -19.29% | 6.50% | -8.48% | 10.62% |
| 2017 | 4.32% | 5.52% | -2.61% | -8.05% | -24.82% | 42.72% | -20.41% | -1.71% | 34.78% | 0.39% | 16.32% | -11.60% | 15.11% |
| 2016 | -22.41% | -6.84% | -8.96% | 11.61% | 4.06% | 37.29% | 9.14% | -9.95% | 3.39% | -24.06% | 6.40% | 4.51% | -9.97% |
| 2015 | -0.25% | 14.39% | 34.86% | -1.49% | -6.20% | -18.05% | -6.65% | -16.94% | -18.99% | 12.33% | 12.52% | 6.04% | -1.91% |
| 2014 | -53.05% | 11.97% | 71.01% | -8.90% | -12.79% | -14.67% | 11.72% | -3.78% | 3.92% | -10.63% | -3.76% | 27.97% | -25.05% |
Risk-Adjusted Performance
Risk-Adjusted Performance Rank
The current rank of IOVA is 4, meaning it’s performing worse than 96% of other stocks on our website when it comes to balancing risk and reward. Below is a breakdown of how it compares using common performance measures.
Risk-Adjusted Performance Indicators
The charts below present risk-adjusted performance metrics for Iovance Biotherapeutics, Inc. (IOVA) and compare them to a chosen benchmark (^GSPC). These indicators evaluate an investment's returns against its associated risks.
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Worst Drawdowns
The table below displays the maximum drawdowns of the Iovance Biotherapeutics, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Iovance Biotherapeutics, Inc. was 99.37%, occurring on Apr 12, 2013. The portfolio has not yet recovered.
The current Iovance Biotherapeutics, Inc. drawdown is 98.01%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
|---|---|---|---|---|---|---|
| -99.37% | Jun 8, 2011 | 464 | Apr 12, 2013 | — | — | — |
| -13.51% | Nov 16, 2010 | 4 | Nov 19, 2010 | 7 | Dec 1, 2010 | 11 |
| -12.7% | Mar 9, 2011 | 4 | Mar 14, 2011 | 33 | Apr 29, 2011 | 37 |
| -9.09% | Oct 19, 2010 | 4 | Oct 22, 2010 | 5 | Oct 29, 2010 | 9 |
| -7.56% | Dec 6, 2010 | 3 | Dec 8, 2010 | 4 | Dec 14, 2010 | 7 |
Volatility
Volatility Chart
The current Iovance Biotherapeutics, Inc. volatility is 26.25%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Iovance Biotherapeutics, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Earnings Per Share
The chart presents the Earnings Per Share (EPS) performance of Iovance Biotherapeutics, Inc., comparing actual results with analytics estimates. The company has exceeded analyst expectations for EPS in the past quarter, achieving a 2.8% positive surprise.
Valuation
The Valuation section provides an overview of how Iovance Biotherapeutics, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for IOVA compared to other companies in the Biotechnology industry. IOVA currently has a PEG ratio of 0.0. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for IOVA relative to other companies in the Biotechnology industry. Currently, IOVA has a P/S ratio of 7.1. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for IOVA in comparison with other companies in the Biotechnology industry. Currently, IOVA has a P/B value of 1.6. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |